HomeAI · summaries
Storia in 8 fonti
Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits
Eli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoarthritis pain in adults with obesity. Patients also experienced substantial weight loss. These findings were shared at an American Diabetes Association conference. Retatrutide targets multiple hormones related to obesity and diabetes.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Retatrutide benefits in obesity, type 2 diabetes ‘quite staggering’
NEW ORLEANS —A triple receptor agonist provided weight loss for adults with obesity, with or without type 2 diabetes, to an extent not seen with previous pharmacotherapy options,…
- ·
morningstar.com
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea,…
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential…
- ·
statnews.com
Lilly shares safety, tolerability data on its next-gen obesity drug
Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.
- ·
independent.co.uk
Eli Lilly’s new weight loss drug may also help sleep apnea according to Phase 3 data
The same trial also revealed retatrutide could offer substantial relief for knee osteoarthritis pain, reducing it by up to 73.1%
- ·
economictimes.indiatimes.com
Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits
Eli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoarthritis pain in adults with obesity.…
- ·
newsbytesapp.com
Eli Lilly's obesity drug shows promise in treating sleep apnea
Eli Lilly's retatrutide significantly reduces sleep apnea severity, knee osteoarthritis pain, and promotes substantial weight loss in adults with obesity, trial results reveal.
- ·
markets.businessinsider.com
Eli Lilly’s (LLY) New Drug Gives Investors a Wake-Up Call as Data Bolsters the Stock’s Growth Story
Eli Lilly and Company (LLY) gave investors another reason to watch its obesity pipeline after new late-stage data showed that its experimental d...
- ·
g1.globo.com
Retatrutida: pesquisa mostra perda de até 28% do peso com nova caneta | G1
Pesquisa foi publicada na revista 'Lancet' e mostra que substância pode gerar perda de peso semelhante à bariátrica, abrindo uma nova fronteira no tratamento. Medicamento ainda…
- ·
US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss market
Lilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity, at the American Diabetes…